pazopanib + carboplatin

Pazopanib is an oral, multi-targeted receptor tyrosine kinase inhibitor (TKI) that inhibits vascular endothelial growth factor receptors (VEGFR-1, -2, and -3), platelet-derived growth factor receptors (PDGFR-α and -β), and the stem cell factor receptor (c-Kit). By blocking these pathways, pazopanib inhibits tumor angiogenesis and cell proliferation. It is FDA-approved for advanced renal cell carcinoma and soft tissue sarcoma. In the specific context of the New Mexico Cancer Research Alliance, pazopanib is being investigated in a Phase I combination study with carboplatin, a platinum-based chemotherapeutic agent that functions as a DNA alkylator to induce apoptosis in rapidly dividing cancer cells. This combination therapy is being evaluated for its safety and efficacy in patients with advanced solid malignancies.

Brand names

Votrient

Other names

pazopanib hydrochloridecarboplatinumPazopanib and Carboplatin